{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:50:29Z","timestamp":1793836229174,"version":"4.6.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Boesenbergia rotunda<\/jats:italic>\n                      (fingerroot) is widely used in traditional medicine, and its bioactive compound panduratin A has demonstrated potent antiviral properties. However, the mechanistic basis underlying its anti-hepatitis B virus (HBV) activity remains to be fully elucidated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      HBV-infected human hepatocytes (imHCs) were treated with\n                      <jats:italic>B. rotunda<\/jats:italic>\n                      extract, panduratin A, or pinostrobin. Intracellular HBV DNA, secreted HBsAg and HBeAg, and pregenomic RNA (pgRNA) were quantified in dose- and time-dependent experiments. Luciferase reporter assays were used to assess HBV promoter activity. The roles of HNF1\u03b1 and HNF4\u03b1 were evaluated by siRNA-mediated knockdown and ectopic gene expression. Drug interaction studies were performed using the KDM5 inhibitor GS-5801 and the capsid assembly modulator NVR-3778. A 3D liver spheroid model was used to validate antiviral effects on HBV DNA and cccDNA. Gene interaction network analysis was conducted to identify central regulatory pathways.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic>B. rotunda<\/jats:italic>\n                      extract, panduratin A, and pinostrobin significantly suppressed intracellular HBV DNA, HBsAg, HBeAg, and pgRNA. Panduratin A exhibited the strongest antiviral activity and inhibited preS1, preS2, and core promoter activities. Panduratin A markedly downregulated HNF1\u03b1 expression, with only modest effects on HNF4\u03b1. Knockdown of HNF1\u03b1 significantly reduced the antiviral efficacy of panduratin A, whereas ectopic HNF1\u03b1 expression rescued its inhibitory effects. Co-treatment with GS-5801 produced synergistic activity, and combination with NVR-3778 yielded additive antiviral effects. In 3D liver spheroids, panduratin A reduced intracellular HBV DNA and cccDNA with minimal cytotoxicity. Network analysis further identified HNF1\u03b1 as a key regulatory node modulated by panduratin A.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Panduratin A is a potent anti-HBV compound that acts primarily through HNF1\u03b1-dependent suppression of HBV transcription and replication. Its efficacy in combination therapy and in 3D liver models highlights its potential as a promising candidate for future HBV treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13020-025-01285-w","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:02:19Z","timestamp":1767744139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Panduratin A from Boesenbergia rotunda suppresses hepatitis B virus by targeting HNF1\u03b1 and synergizing with antiviral agents"],"prefix":"10.1186","volume":"21","author":[{"given":"Piyanoot","family":"Thongsri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyut","family":"Pewkliang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suparerk","family":"Borwornpinyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adisak","family":"Wongkajornsilp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pakatip","family":"Ruenraroengsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usanarat","family":"Anurathapan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhasnee","family":"Sobhonslidsuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suradej","family":"Hongeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khanit","family":"Sa-ngiamsuntorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"issue":"2","key":"1285_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s12072-018-9912-8","volume":"13","author":"J Lang","year":"2019","unstructured":"Lang J, Neumann-Haefelin C, Thimme R. Immunological cure of HBV infection. Hepatol Int. 2019;13(2):113\u201324.","journal-title":"Hepatol Int"},{"key":"1285_CR2","doi-asserted-by":"publisher","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","volume":"4","author":"MF Yuen","year":"2018","unstructured":"Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, et al. Hepatitis B virus infection. Nat Rev Dis Primers. 2018;4:18035.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"1285_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261\u201383.","journal-title":"Hepatology"},{"issue":"10003","key":"1285_CR4","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546\u201355.","journal-title":"Lancet"},{"issue":"3","key":"1285_CR5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.anai.2018.03.017","volume":"121","author":"TV Saco","year":"2018","unstructured":"Saco TV, Strauss AT, Ledford DK. Hepatitis B vaccine nonresponders: possible mechanisms and solutions. Ann Allergy Asthma Immunol. 2018;121(3):320\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1285_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00760-9","author":"Y-C Hsu","year":"2023","unstructured":"Hsu Y-C, Huang DQ, Nguyen MH. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol. 2023. https:\/\/doi.org\/10.1038\/s41575-023-00760-9.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"1285_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3350\/kjhep.2011.17.2.87","volume":"17","author":"SY Kwon","year":"2011","unstructured":"Kwon SY, Lee CH. Epidemiology and prevention of hepatitis B virus infection. Korean J Hepatol. 2011;17(2):87\u201395.","journal-title":"Korean J Hepatol"},{"issue":"1","key":"1285_CR8","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/hep.28280","volume":"63","author":"AS Lok","year":"2016","unstructured":"Lok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology. 2016;63(1):284\u2013306.","journal-title":"Hepatology"},{"issue":"3","key":"1285_CR9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cld.2019.04.006","volume":"23","author":"U Lopatin","year":"2019","unstructured":"Lopatin U. Drugs in the pipeline for HBV. Clin Liver Dis. 2019;23(3):535\u201355.","journal-title":"Clin Liver Dis"},{"issue":"1 Suppl","key":"1285_CR10","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jhep.2016.01.027","volume":"64","author":"S Tong","year":"2016","unstructured":"Tong S, Revill P. Overview of hepatitis B viral replication and genetic variability. J Hepatol. 2016;64(1 Suppl):S4-s16.","journal-title":"J Hepatol"},{"issue":"6","key":"1285_CR11","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s12072-017-9829-7","volume":"11","author":"P Karayiannis","year":"2017","unstructured":"Karayiannis P. Hepatitis B virus: virology, molecular biology, life cycle and intrahepatic spread. Hepatol Int. 2017;11(6):500\u20138.","journal-title":"Hepatol Int"},{"issue":"12","key":"1285_CR12","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","volume":"64","author":"M Nassal","year":"2015","unstructured":"Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015;64(12):1972\u201384.","journal-title":"Gut"},{"key":"1285_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(18)31226-1","author":"R Erken","year":"2018","unstructured":"Erken R, Stelma F, Roy E, Dian\u00e9 S, Andr\u00e9 P, Vonderscher J, et al. First clinical evaluation in chronic hepatitis B patients of the synthetic farnesoid X receptor agonist EYP001. J Hepatol. 2018. https:\/\/doi.org\/10.1016\/S0168-8278(18)31226-1.","journal-title":"J Hepatol"},{"issue":"31","key":"1285_CR14","doi-asserted-by":"publisher","first-page":"7017","DOI":"10.3748\/wjg.v22.i31.7017","volume":"22","author":"DH Kim","year":"2016","unstructured":"Kim DH, Kang HS, Kim KH. Roles of hepatocyte nuclear factors in hepatitis B virus infection. World J Gastroenterol. 2016;22(31):7017\u201329.","journal-title":"World J Gastroenterol"},{"issue":"5662","key":"1285_CR15","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1126\/science.1089769","volume":"303","author":"DT Odom","year":"2004","unstructured":"Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, et al. Control of pancreas and liver gene expression by HNF transcription factors. Science. 2004;303(5662):1378\u201381.","journal-title":"Science"},{"key":"1285_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-77003-3","author":"P Kanjanasirirat","year":"2020","unstructured":"Kanjanasirirat P, Suksatu A, Manopwisedjaroen S, Munyoo B, Tuchinda P, Jearawuttanakul K, et al. High-content screening of Thai medicinal plants reveals Boesenbergia rotunda extract and its component Panduratin A as anti-SARS-CoV-2 agents. Sci Rep. 2020. https:\/\/doi.org\/10.1038\/s41598-020-77003-3.","journal-title":"Sci Rep"},{"issue":"3","key":"1285_CR17","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.3390\/ijms25031427","volume":"25","author":"AK Linn","year":"2024","unstructured":"Linn AK, Manopwisedjaroen S, Kanjanasirirat P, Borwornpinyo S, Hongeng S, Phanthong P, et al. Unveiling the antiviral properties of Panduratin A through SARS-CoV-2 infection modeling in cardiomyocytes. Int J Mol Sci. 2024;25(3):1427.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1285_CR18","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.bmc.2005.10.019","volume":"14","author":"S Cheenpracha","year":"2006","unstructured":"Cheenpracha S, Karalai C, Ponglimanont C, Subhadhirasakul S, Tewtrakul S. Anti-HIV-1 protease activity of compounds from Boesenbergia pandurata. Bioorg Med Chem. 2006;14(6):1710\u20134.","journal-title":"Bioorg Med Chem"},{"key":"1285_CR19","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/137083","volume":"2012","author":"SM Salama","year":"2012","unstructured":"Salama SM, Bilgen M, Al Rashdi AS, Abdulla MA. Efficacy of Boesenbergia rotunda treatment against thioacetamide-induced liver cirrhosis in a rat model. Evid Based Complement Alternat Med. 2012;2012:137083.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"9","key":"1285_CR20","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/apm.12878","volume":"126","author":"SM Salama","year":"2018","unstructured":"Salama SM, Ibrahim IAA, Shahzad N, Al-Ghamdi S, Ayoub N, AlRashdi AS, et al. Hepatoprotectivity of panduratin A against liver damage: in vivo demonstration with a rat model of cirrhosis induced by thioacetamide. APMIS. 2018;126(9):710\u201321.","journal-title":"APMIS"},{"issue":"10","key":"1285_CR21","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/v11100952","volume":"11","author":"K Sa-ngiamsuntorn","year":"2019","unstructured":"Sa-ngiamsuntorn K, Thongsri P, Pewkliang Y, Wongkajornsilp A, Kongsomboonchoke P, Suthivanich P, et al. An immortalized hepatocyte-like cell line (imHC) accommodated complete viral lifecycle, viral persistence form, cccDNA and eventual spreading of a clinically-isolated HBV. Viruses. 2019;11(10):952.","journal-title":"Viruses"},{"issue":"1","key":"1285_CR22","doi-asserted-by":"publisher","first-page":"19125","DOI":"10.1038\/s41598-021-98243-x","volume":"11","author":"P Thongsri","year":"2021","unstructured":"Thongsri P, Pewkliang Y, Borwornpinyo S, Wongkajornsilp A, Hongeng S, Sa-ngiamsuntorn K. Curcumin inhibited hepatitis B viral entry through NTCP binding. Sci Rep. 2021;11(1):19125.","journal-title":"Sci Rep"},{"key":"1285_CR23","volume":"183","author":"K Sa-ngiamsuntorn","year":"2022","unstructured":"Sa-ngiamsuntorn K, Thongsri P, Pewkliang Y, Borwornpinyo S, Wongkajornsilp A. A competent hepatocyte model examining hepatitis B virus entry through sodium taurocholate cotransporting polypeptide as a therapeutic target. JoVE. 2022;183:e63761.","journal-title":"JoVE"},{"issue":"3","key":"1285_CR24","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jmoldx.2018.01.010","volume":"20","author":"J-T Huang","year":"2018","unstructured":"Huang J-T, Yang Y, Hu Y-M, Liu X-H, Liao M-Y, Morgan R, et al. A highly sensitive and robust method for hepatitis B virus covalently closed circular DNA detection in single cells and serum. J Mol Diagn. 2018;20(3):334\u201343.","journal-title":"J Mol Diagn"},{"issue":"suppl_2","key":"1285_CR25","doi-asserted-by":"publisher","first-page":"W214","DOI":"10.1093\/nar\/gkq537","volume":"38","author":"D Warde-Farley","year":"2010","unstructured":"Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38(suppl_2):W214\u201320.","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"1285_CR26","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1016\/j.bmcl.2005.12.075","volume":"16","author":"TS Kiat","year":"2006","unstructured":"Kiat TS, Pippen R, Yusof R, Ibrahim H, Khalid N, Rahman NA. Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of fingerroot, Boesenbergia rotunda (L.), towards dengue-2 virus NS3 protease. Bioorg Med Chem Lett. 2006;16(12):3337\u201340.","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"1285_CR27","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.foodchem.2008.12.057","volume":"115","author":"S Tewtrakul","year":"2009","unstructured":"Tewtrakul S, Subhadhirasakul S, Karalai C, Ponglimanont C, Cheenpracha S. Anti-inflammatory effects of compounds from Kaempferia parviflora and Boesenbergia pandurata. Food Chem. 2009;115(2):534\u20138.","journal-title":"Food Chem"},{"issue":"12","key":"1285_CR28","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1055\/s-2003-45190","volume":"69","author":"JM Yun","year":"2003","unstructured":"Yun JM, Kwon H, Hwang JK. In vitro anti-inflammatory activity of panduratin A isolated from Kaempferia pandurata in RAW264.7 cells. Planta Med. 2003;69(12):1102\u20138.","journal-title":"Planta Med"},{"issue":"9","key":"1285_CR29","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1271\/bbb.60086","volume":"70","author":"K Shindo","year":"2006","unstructured":"Shindo K, Kato M, Kinoshita A, Kobayashi A, Koike Y. Analysis of antioxidant activities contained in the Boesenbergia pandurata Schult. rhizome. Biosci Biotechnol Biochem. 2006;70(9):2281\u20134.","journal-title":"Biosci Biotechnol Biochem"},{"issue":"6","key":"1285_CR30","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1248\/bpb.28.1083","volume":"28","author":"JH Sohn","year":"2005","unstructured":"Sohn JH, Han KL, Lee SH, Hwang JK. Protective effects of panduratin A against oxidative damage of tert-butylhydroperoxide in human HepG2 cells. Biol Pharm Bull. 2005;28(6):1083\u20136.","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"1285_CR31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s11418-006-0100-0","volume":"61","author":"C Kirana","year":"2007","unstructured":"Kirana C, Jones GP, Record IR, McIntosh GH. Anticancer properties of panduratin A isolated from Boesenbergia pandurata (Zingiberaceae). J Nat Med. 2007;61(2):131\u20137.","journal-title":"J Nat Med"},{"issue":"7","key":"1285_CR32","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/carcin\/bgi348","volume":"27","author":"JM Yun","year":"2006","unstructured":"Yun JM, Kweon MH, Kwon H, Hwang JK, Mukhtar H. Induction of apoptosis and cell cycle arrest by a chalcone panduratin A isolated from Kaempferia pandurata in androgen-independent human prostate cancer cells PC3 and DU145. Carcinogenesis. 2006;27(7):1454\u201364.","journal-title":"Carcinogenesis"},{"issue":"1","key":"1285_CR33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2334\/josnusd.51.87","volume":"51","author":"Y Rukayadi","year":"2009","unstructured":"Rukayadi Y, Lee KH, Hwang JK. Activity of panduratin A isolated from Kaempferia pandurata Roxb. against multi-species oral biofilms in vitro. J Oral Sci. 2009;51(1):87\u201395.","journal-title":"J Oral Sci"},{"issue":"10","key":"1285_CR34","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.1128\/AAC.00624-09","volume":"53","author":"Y Rukayadi","year":"2009","unstructured":"Rukayadi Y, Lee K, Han S, Yong D, Hwang JK. In vitro activities of panduratin A against clinical Staphylococcus strains. Antimicrob Agents Chemother. 2009;53(10):4529\u201332.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"1285_CR35","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1055\/s-2008-1081352","volume":"74","author":"JS Shim","year":"2008","unstructured":"Shim JS, Kwon YY, Han YS, Hwang JK. Inhibitory effect of panduratin A on UV-induced activation of mitogen-activated protein kinases (MAPKs) in dermal fibroblast cells. Planta Med. 2008;74(12):1446\u201350.","journal-title":"Planta Med"},{"issue":"3","key":"1285_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1055\/s-2008-1034297","volume":"74","author":"JS Shim","year":"2008","unstructured":"Shim JS, Kwon YY, Hwang JK. The effects of panduratin A isolated from Kaempferia pandurata on the expression of matrix metalloproteinase-1 and type-1 procollagen in human skin fibroblasts. Planta Med. 2008;74(3):239\u201344.","journal-title":"Planta Med"},{"issue":"1","key":"1285_CR37","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3390\/ijms13010994","volume":"13","author":"DY Kim","year":"2012","unstructured":"Kim DY, Kim MS, Sa BK, Kim MB, Hwang JK. Boesenbergia pandurata attenuates diet-induced obesity by activating AMP-activated protein kinase and regulating lipid metabolism. Int J Mol Sci. 2012;13(1):994\u20131005.","journal-title":"Int J Mol Sci"},{"key":"1285_CR38","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.2147\/DDDT.S453847","volume":"18","author":"T Kongratanapasert","year":"2024","unstructured":"Kongratanapasert T, Boonyarattanasoonthorn T, Supannapan K, Hongeng S, Khemawoot P. Oral bioavailability, tissue distribution, metabolism, and excretion of panduratin A from Boesenbergia rotunda extract in healthy rats. Drug Des Devel Ther. 2024;18:2905\u201317.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"1285_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e12780","volume":"9","author":"P Boonserm","year":"2023","unstructured":"Boonserm P, Khunrae P, Sutthibutpong T. A computational study on the molecular mechanisms of panduratin A as a potential inhibitor on SARS-CoV-2 protein targets. Heliyon. 2023;9(1):e12780.","journal-title":"Heliyon"},{"issue":"1","key":"1285_CR40","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/1472-6882-13-279","volume":"13","author":"SM Salama","year":"2013","unstructured":"Salama SM, AlRashdi AS, Abdulla MA, Hassandarvish P, Bilgen M. Protective activity of panduratin A against Thioacetamide-induced oxidative damage: demonstration with in vitro experiments using WRL-68 liver cell line. BMC Complement Altern Med. 2013;13(1):279.","journal-title":"BMC Complement Altern Med"},{"issue":"23","key":"1285_CR41","doi-asserted-by":"publisher","first-page":"13689","DOI":"10.1128\/JVI.02035-14","volume":"88","author":"C Ko","year":"2014","unstructured":"Ko C, Lee S, Windisch MP, Ryu W-S. DDX3 DEAD-box RNA helicase is a host factor that restricts hepatitis B virus replication at the transcriptional level. J Virol. 2014;88(23):13689\u201398.","journal-title":"J Virol"},{"key":"1285_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104925","volume":"182","author":"S Tsukuda","year":"2020","unstructured":"Tsukuda S, Watashi K. Hepatitis B virus biology and life cycle. Antiviral Res. 2020;182:104925.","journal-title":"Antiviral Res"},{"issue":"2","key":"1285_CR43","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3748\/wjg.v20.i2.425","volume":"20","author":"J Quarleri","year":"2014","unstructured":"Quarleri J. Core promoter: a critical region where the hepatitis B virus makes decisions. World J Gastroenterol. 2014;20(2):425\u201335.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"1285_CR44","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1046\/j.1365-2893.2002.00381.x","volume":"9","author":"N Moolla","year":"2002","unstructured":"Moolla N, Kew M, Arbuthnot P. Regulatory elements of hepatitis B virus transcription. J Viral Hepat. 2002;9(5):323\u201331.","journal-title":"J Viral Hepat"},{"issue":"2","key":"1285_CR45","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3390\/v12020160","volume":"12","author":"KL Turton","year":"2020","unstructured":"Turton KL, Meier-Stephenson V, Badmalia MD, Coffin CS, Patel TR. Host transcription factors in hepatitis B virus RNA synthesis. Viruses. 2020;12(2):160.","journal-title":"Viruses"},{"issue":"8","key":"1285_CR46","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.3390\/cells10082026","volume":"10","author":"EC Tachmatzidi","year":"2021","unstructured":"Tachmatzidi EC, Galanopoulou O, Talianidis I. Transcription control of liver development. Cells. 2021;10(8):2026.","journal-title":"Cells"},{"issue":"1","key":"1285_CR47","first-page":"443","volume":"13","author":"W Guo","year":"1993","unstructured":"Guo W, Chen M, Yen TSB, Ou J-H. Hepatocyte-specific expression of the hepatitis B virus core promoter depends on both positive and negative regulation. Mol Cell Biol. 1993;13(1):443\u20138.","journal-title":"Mol Cell Biol"},{"issue":"11","key":"1285_CR48","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.1128\/jvi.65.11.5774-5781.1991","volume":"65","author":"AK Raney","year":"1991","unstructured":"Raney AK, Easton AJ, Milich DR, McLachlan A. Promoter-specific transactivation of hepatitis B virus transcription by a glutamine- and proline-rich domain of hepatocyte nuclear factor 1. J Virol. 1991;65(11):5774\u201381.","journal-title":"J Virol"},{"issue":"4","key":"1285_CR49","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1128\/JVI.77.4.2489-2499.2003","volume":"77","author":"X Yu","year":"2003","unstructured":"Yu X, Mertz JE. Distinct modes of regulation of transcription of hepatitis B virus by the nuclear receptors HNF4alpha and COUP-TF1. J Virol. 2003;77(4):2489\u201399.","journal-title":"J Virol"},{"issue":"3","key":"1285_CR50","first-page":"1353","volume":"11","author":"DX Zhou","year":"1991","unstructured":"Zhou DX, Yen TS. The ubiquitous transcription factor Oct-1 and the liver-specific factor HNF-1 are both required to activate transcription of a hepatitis B virus promoter. Mol Cell Biol. 1991;11(3):1353\u20139.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"1285_CR51","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0923-2516(98)80085-X","volume":"149","author":"WX Wang","year":"1998","unstructured":"Wang WX, Li M, Wu X, Wang Y, Li ZP. HNF1 is critical for the liver-specific function of HBV enhancer II. Res Virol. 1998;149(2):99\u2013108.","journal-title":"Res Virol"},{"issue":"36","key":"1285_CR52","doi-asserted-by":"publisher","first-page":"30181","DOI":"10.1074\/jbc.M112.370312","volume":"287","author":"Z Zhao","year":"2012","unstructured":"Zhao Z, Hong W, Zeng Z, Wu Y, Hu K, Tian X, et al. Mucroporin-M1 inhibits hepatitis B virus replication by activating the mitogen-activated protein kinase (MAPK) pathway and down-regulating HNF4\u03b1 in vitro and in vivo. J Biol Chem. 2012;287(36):30181\u201390.","journal-title":"J Biol Chem"},{"issue":"2","key":"1285_CR53","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41401-019-0302-0","volume":"41","author":"ZY Wang","year":"2020","unstructured":"Wang ZY, Li YQ, Guo ZW, Zhou XH, Lu MD, Xue TC, et al. ERK1\/2-HNF4\u03b1 axis is involved in epigallocatechin-3-gallate inhibition of HBV replication. Acta Pharmacol Sin. 2020;41(2):278\u201385.","journal-title":"Acta Pharmacol Sin"},{"key":"1285_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104568","volume":"170","author":"L Li","year":"2019","unstructured":"Li L, Li Y, Xiong Z, Shu W, Yang Y, Guo Z, et al. FoxO4 inhibits HBV core promoter activity through ERK-mediated downregulation of HNF4\u03b1. Antiviral Res. 2019;170:104568.","journal-title":"Antiviral Res"},{"issue":"2","key":"1285_CR55","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/jcmm.16137","volume":"25","author":"M Xie","year":"2021","unstructured":"Xie M, Guo H, Lou G, Yao J, Liu Y, Sun Y, et al. Neddylation inhibitor MLN4924 has anti-HBV activity via modulating the ERK-HNF1\u03b1-C\/EBP\u03b1-HNF4\u03b1 axis. J Cell Mol Med. 2021;25(2):840\u201354.","journal-title":"J Cell Mol Med"},{"issue":"12","key":"1285_CR56","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00011-019-01284-2","volume":"68","author":"Y Pan","year":"2019","unstructured":"Pan Y, Ke Z, Ye H, Sun L, Ding X, Shen Y, et al. Saikosaponin C exerts anti-HBV effects by attenuating HNF1\u03b1 and HNF4\u03b1 expression to suppress HBV pgRNA synthesis. Inflamm Res. 2019;68(12):1025\u201334.","journal-title":"Inflamm Res"},{"key":"1285_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2020.115131","volume":"403","author":"C Xia","year":"2020","unstructured":"Xia C, Tang W, Geng P, Zhu H, Zhou W, Huang H, et al. Baicalin down-regulating hepatitis B virus transcription depends on the liver-specific HNF4\u03b1-HNF1\u03b1 axis. Toxicol Appl Pharmacol. 2020;403:115131.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1285_CR58","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.taap.2017.03.016","volume":"323","author":"H Huang","year":"2017","unstructured":"Huang H, Zhou W, Zhu H, Zhou P, Shi X. Baicalin benefits the anti-HBV therapy via inhibiting HBV viral RNAs. Toxicol Appl Pharmacol. 2017;323:36\u201343.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"20","key":"1285_CR59","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889\u201398.","journal-title":"N Engl J Med"},{"issue":"10","key":"1285_CR60","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.cmi.2016.05.027","volume":"22","author":"JE Arends","year":"2016","unstructured":"Arends JE, Kracht PA, Hoepelman AI. Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice. Clin Microbiol Infect. 2016;22(10):846\u201352.","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"1285_CR61","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0166-3542(02)00071-2","volume":"55","author":"S Lewin","year":"2002","unstructured":"Lewin S, Walters T, Locarnini S. Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies. Antivir Res. 2002;55(3):381\u201396.","journal-title":"Antivir Res"},{"issue":"5","key":"1285_CR62","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1177\/1087057114521867","volume":"19","author":"W Zhao","year":"2014","unstructured":"Zhao W, Sachsenmeier K, Zhang L, Sult E, Hollingsworth RE, Yang H. A new bliss independence model to analyze drug combination data. J Biomol Screen. 2014;19(5):817\u201321.","journal-title":"J Biomol Screen"},{"key":"1285_CR63","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01734-18","author":"AM Lam","year":"2019","unstructured":"Lam AM, Espiritu C, Vogel R, Ren S, Lau V, Kelly M, et al. Preclinical characterization of NVR 3-778, a first-in-class capsid assembly modulator against hepatitis B virus. Antimicrob Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/AAC.01734-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"1285_CR64","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02441-16","author":"E Lomonosova","year":"2017","unstructured":"Lomonosova E, Zlotnick A, Tavis JE. Synergistic interactions between hepatitis B virus RNase H antagonists and other inhibitors. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/AAC.02441-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1285_CR65","doi-asserted-by":"publisher","first-page":"2200169","DOI":"10.1002\/adtp.202200169","volume":"6","author":"A Sae-be","year":"2023","unstructured":"Sae-be A, Wiwatpanit T, Varatthan T, Namporn T, Laungkulldej S, Thiabma R, et al. Comparative study between the 3D-Liver spheroid models developed from HepG2 and immortalized hepatocyte-like cells with primary hepatic stellate coculture for drug metabolism analysis and anticancer drug screening. Adv Ther. 2023;6(2):2200169.","journal-title":"Adv Ther"},{"issue":"7","key":"1285_CR66","doi-asserted-by":"publisher","first-page":"1800347","DOI":"10.1002\/biot.201800347","volume":"14","author":"VM Lauschke","year":"2019","unstructured":"Lauschke VM, Shafagh RZ, Hendriks DFG, Ingelman-Sundberg M. 3D primary hepatocyte culture systems for analyses of liver diseases, drug metabolism, and toxicity: emerging culture paradigms and applications. Biotechnol J. 2019;14(7):1800347.","journal-title":"Biotechnol J"},{"key":"1285_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2024.110265","volume":"600","author":"CE Jones","year":"2024","unstructured":"Jones CE, Dangas G, Norris AC, Koenig M, Li D-Y, Shue TM, et al. Long-term 3D cell culture models for hepatitis B virus studies. Virology. 2024;600:110265.","journal-title":"Virology"},{"issue":"4","key":"1285_CR68","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.virs.2022.05.002","volume":"37","author":"Y Song","year":"2022","unstructured":"Song Y, Shou S, Guo H, Gao Z, Liu N, Yang Y, et al. Establishment and characterization of a new cell culture system for hepatitis B virus replication and infection. Virol Sin. 2022;37(4):558\u201368.","journal-title":"Virol Sin"},{"issue":"7","key":"1285_CR69","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1111\/j.1462-5822.2008.01141.x","volume":"10","author":"M Quasdorff","year":"2008","unstructured":"Quasdorff M, H\u00f6sel M, Odenthal M, Zedler U, Bohne F, Gripon P, et al. A concerted action of HNF4\u03b1 and HNF1\u03b1 links hepatitis B virus replication to hepatocyte differentiation. Cell Microbiol. 2008;10(7):1478\u201390.","journal-title":"Cell Microbiol"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-025-01285-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-025-01285-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-025-01285-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:02:21Z","timestamp":1767744141000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13020-025-01285-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1285"],"URL":"https:\/\/doi.org\/10.1186\/s13020-025-01285-w","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}